---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-089278"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:49:33.025898+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO Q2 net loss $53M; advances RGX-202 pivotal and RGX-121 BLA

## Summary
- Q2 2024 net loss of $53.0M ($1.05 per share); revenue $22.3M (up 12% YoY) on Zolgensma royalties.
- Cash $327.3M at June 30, 2024; runway into 2026, excluding potential $200M AbbVie milestone.
- RGX-202 (Duchenne): consistent high microdystrophin expression; EOP2 supports accelerated approval; pivotal trial start Q4 2024.
- RGX-121 (MPS II): rolling BLA submission begins Q3 2024 under accelerated approval pathway.
- ABBV-RGX-314 (diabetic retinopathy): EOP2 meeting accelerated to Q4 2024; global pivotal trial planned H1 2025.

## SEC filing metadata
- accession: 0000950170-24-089278
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000095017024089278/0000950170-24-089278-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000095017024089278/rgnx-20240801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-089278
- JSON: https://secwatch.observer/filing/0000950170-24-089278.json
- Plain text: https://secwatch.observer/filing/0000950170-24-089278.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.